Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
Besides Wall Street's top -and-bottom-line estimates for AbbVie (ABBV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.
Merck and AbbVie are included in this Analyst Blog.
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.